Nts in Any Remedy GroupPatients with Adverse Occasion (AE), (n) Any AE Cognitive disorder Disturbance in consideration Dizziness Migraine Paraesthesia Sinusitis Nausea Neck pain Fatigue Depression Vision blurred Decreased appetite two.7 (six) 0 7.0 (ten) ten.6 (15) 5.0 (14) 5.3 (15) 3.8 (3) 0 5.five (12) 0.5 (1) 4.5 (10) 0.5 (1) 1.8 (four) 6.three (9) 13.four (19) 2.1 (3) 13.four (19) 5.6 (eight) two.7 (6) 2.7 (6) 0.five (1) 12.7 (18) 2.1 (three) 31.0 (44) eight.2 (23) 2.5 (7) 16.0 (45) 5.7 (16) 7.1 (20) 4.three (12) 7.1 (20) 3.5 (10) 1.three (1) five.0 (4) 0 6.three (five) 0 six.three (5) 0 two.five (two) OnabotulinumtoxinA (n=220) Topiramate Total Switched to (n=142) (N=282) OnabotulinumtoxinA (n=80)P10 Chronic migraine remedy with erenumab: Responder rates Hans-Christoph Diener1, Jan Brandes2, David Dolezil3, Marshall C Freeman4, Peter J McAllister5, Paul Winner6, Sunfa Cheng7, Dean K Leonardi7, Robert A Lenz7, Daniel D Mikol7 1 University Duisburg-Essen, Essen, Germany; 2Nashville Neuroscience Group, Nashville, TN, USA; 3Prague Drinabant MedChemExpress Headache Center, DADO Medical s.r.o., Prague, Czech Republic; 4Headache Wellness Center, Greensboro, NC, USA; 5New England Institute for Neurology and Headache, Stamford, CT, USA; 6Palm Beach Headache Center, West Palm Beach, FL, USA; 7 Amgen Inc., Thousand Oaks, CA, USA Correspondence: Hans-Christoph Diener ([email protected]) The Journal of Headache and Discomfort 2017, 18(Suppl 1):P10 Background Erenumab (AMG 334) is usually a human anti-calcitonin gene-related peptide (CGRP) receptor antibody becoming evaluated as preventive remedy for chronic migraine (CM). When assessing efficacy of CM treatments by responder rates, there is certainly an unmet need to have for additional productive treatment options. Procedures In a prospective exploratory evaluation of data from a phase 2 study (NCT02066415) in individuals with CM (15 headache daysmonth more than three months with eight migraine days), individuals (N=667) were randomised to erenumab (70 mg or 140 mg as soon as monthly) or placebo. This evaluation integrated calculation of proportions of individuals with 50 , 75 , or 100 reduction in month-to-month migraine days (MMD) from baseline to final four weeks of a 12-week double-blind phase. P-values are determined by odds ratios (ORs) from placebo and will not be adjusted for many comparisons. Outcomes Mean (SD) baseline MMD have been 18.0 (four.6). Drastically higher proportions of sufferers treated with erenumab 70 mg or 140 mg experienced a 50 reduction from baseline in MMD compared with placebo at Week 12 (39.9 and 41.two , vs 23.5 ; OR: two.two [p0.001] and two.3 [p0.001]). The 75 responder prices were larger for patients treated with erenumab 70 mg or 140 mg compared with placebo (17.0 and 20.9 , vs 7.8 ; OR: 2.4 [p=0.002] and three.1 [p0.001]). Likewise, the one hundred responder rates were higher for sufferers treated with erenumab 70 mg or 140 mg compared with placebo (four.3 and 2.7 , vs 0.four ; OR: 12.six [p=0.002] and 8.1 [p=0.026]). Conclusions Erenumab therapy resulted in higher proportions of sufferers with CM experiencing 50 , 75 , and one hundred reduction in MMD as compared with placebo.45.five (one hundred) 0.five (1)76.eight (109) 12.7 (18) 7.7 (11)62.four (176) six.4 (18) three.9 (11)41.three (33) 1.three (1)P11 Systematic Cochrane overview of botulinum toxins for the prevention of migraine in adults Alexandra Sinclair1, Clare P Herd2, Claire L Tomlinson3, Caroline Rick3, WJ Scotton1, Julie Edwards4, Natalie Ives3, Carl E Clarke2 1 Institute of Metabolism and Systems Investigation, University of Birmingham, Birmingham, UK; 2Institute of Applied Wellness Research, University of Birmingham, Birmingham, UK; 3Birmingham Clinical T.
